Regeneus' newly-appointed CEO Leo Lee discusses strategic plans for growth

Wednesday, 30 January 2019

Leo Lee, the newly-appointed CEO of Regeneus Ltd (ASX:RGS), speaks to Proactive Investors about the Australian clinical-stage regenerative medicine company's operations, and the wider scientific field.

The company holds a number of patents, and is focusing on global expansion, as it advances treatments in the areas of osteoarthritis, cancer, and dermatology.

Click the image below to view the original story and complete video interview with Proactive Investors.